Literature DB >> 18601303

Role of cannabinoids in the management of neuropathic pain.

M Isabel Martín Fontelles1, Carlos Goicoechea García.   

Abstract

The treatment of pain, particularly neuropathic pain, is one of the therapeutic applications of cannabis and cannabinoids that is currently under investigation and that stimulates interest among clinicians and basic researchers. Animal pain models, including models of acute, antinociceptive, inflammatory and neuropathic pain, have demonstrated the antinociceptive efficacy of cannabinoids without causing serious alterations in animal behaviour. These data, together with the historic and current empiric use of cannabinoids, support the interest in the analysis of their effectiveness in treating neuropathic pain. The evaluation of controlled trials that focus on the effect of cannabinoids on neuropathic pain reveals that this class of drugs is able to significantly reduce pain perception. Nevertheless, this effect is generally weak and clinical relevance remains under evaluation. Moreover, there is a lack of controlled trials and, in particular, comparisons with other drugs generally used in the treatment of neuropathic pain. Despite the fact that further research is required to achieve a definitive assessment, current data obtained from basic research and from analysis of the available controlled trials indicate that cannabinoids can be accepted as a useful option in the treatment of neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18601303     DOI: 10.2165/00023210-200822080-00003

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  75 in total

1.  CB2 cannabinoid receptor-mediated peripheral antinociception.

Authors:  T P Malan; M M Ibrahim; H Deng; Q Liu; H P Mata; T Vanderah; F Porreca; A Makriyannis
Journal:  Pain       Date:  2001-09       Impact factor: 6.961

2.  Time-related decreases in mu and delta opioid receptors in the superficial dorsal horn of the rat spinal cord following a large unilateral dorsal rhizotomy.

Authors:  D Besse; M C Lombard; J M Besson
Journal:  Brain Res       Date:  1992-04-24       Impact factor: 3.252

3.  The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors.

Authors:  J Guindon; J Desroches; P Beaulieu
Journal:  Br J Pharmacol       Date:  2006-12-18       Impact factor: 8.739

Review 4.  Cannabinoid receptors and pain.

Authors:  R G Pertwee
Journal:  Prog Neurobiol       Date:  2001-04       Impact factor: 11.685

5.  A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats.

Authors:  David Pascual; Carlos Goicoechea; Margarita Suardíaz; María Isabel Martín
Journal:  Pain       Date:  2005-10-04       Impact factor: 6.961

6.  Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes.

Authors:  S Sagan; L Venance; Y Torrens; J Cordier; J Glowinski; C Giaume
Journal:  Eur J Neurosci       Date:  1999-02       Impact factor: 3.386

7.  Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial.

Authors:  Jonathan S Berman; Catherine Symonds; Rolfe Birch
Journal:  Pain       Date:  2004-12       Impact factor: 6.961

Review 8.  Recent developments in the therapeutic potential of cannabinoids.

Authors:  Susan Corey
Journal:  P R Health Sci J       Date:  2005-03       Impact factor: 0.705

9.  Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.

Authors:  Amy C Porter; John-Michael Sauer; Michael D Knierman; Gerald W Becker; Michael J Berna; Jingqi Bao; George G Nomikos; Petra Carter; Frank P Bymaster; Andrea Baker Leese; Christian C Felder
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

10.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

View more
  3 in total

1.  The effect of Neuragen PN on neuropathic pain: A randomized, double blind, placebo controlled clinical trial.

Authors:  Li Li
Journal:  BMC Complement Altern Med       Date:  2010-05-20       Impact factor: 3.659

2.  Intrathecal Injection of JWH-015 Attenuates Bone Cancer Pain Via Time-Dependent Modification of Pro-inflammatory Cytokines Expression and Astrocytes Activity in Spinal Cord.

Authors:  Cui'e Lu; Yue Liu; Bei Sun; Yu'e Sun; Bailing Hou; Yu Zhang; Zhengliang Ma; Xiaoping Gu
Journal:  Inflammation       Date:  2015-10       Impact factor: 4.092

Review 3.  Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.

Authors:  Mariana Babayeva; Haregewein Assefa; Paramita Basu; Sanjeda Chumki; Zvi Loewy
Journal:  Parkinsons Dis       Date:  2016-12-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.